June 4, 2021 07:21 AM EDT

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Max Gelman

Senior Editor

After Bristol Myers Squibb’s $74 billion buyout of Celgene, the industry intensely scrutinized whether or not the Big Pharma would ultimately hit its drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Bris­tol My­ers sued over $6B Cel­gene CVR as trustee claims 'bla­tant mis­con­duc­t' for liso-cel de­lays

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks